Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Milciclib |
Synonyms | |
Therapy Description |
Milciclib (PHA-848125AC) is a TRKA inhibitor with additional activity against CDK1, CDK2, CDK4, CDK5, and CDK7, potentially resulting in decreased tumor cell growth (PMID: 22160853, PMID: 28424962). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Milciclib | PHA-848125AC|PHA-848125|PHA 848125 | CDK1 Inhibitor 13 CDK2 Inhibitor 31 CDK4 Inhibitor 17 CDK5 Inhibitor 8 CDK7 Inhibitor 16 TrkA Receptor Inhibitor 8 | Milciclib (PHA-848125AC) is a TRKA inhibitor with additional activity against CDK1, CDK2, CDK4, CDK5, and CDK7, potentially resulting in decreased tumor cell growth (PMID: 22160853, PMID: 28424962). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A loss | brain glioblastoma multiforme | sensitive | Milciclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Milciclib (PHA-848125AC) resulted in tumor regression in glioma cell line xenograft models with CDKN2A loss (PMID: 23347136). | 23347136 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01301391 | Phase II | Milciclib | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy | Terminated | USA | ITA | 0 |
NCT01011439 | Phase II | Milciclib | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | Terminated | USA | ITA | FRA | 0 |